+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a bivalent vaccine candidate designed to protect adults aged 60 years and older against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV. This Phase 12, randomized, observer-blind, placebo-controlled study involves about 2400 participants and aims to assess the vaccines ability to trigger immune responses and monitor its safety. While several RSV vaccines are approved, there is currently no vaccine for preventing HMPV in older adults. Participants will be assigned to one of 11 groups, receiving different doses of the RSVHMPV vaccine, placebo, or one of four control vaccines. The study includes six dose levels of the RSVHMPV vaccine with predefined antigen ratios. Each participant will be followed for approximately 12 months to allow comprehensive evaluation. The study is conducted across multiple centers and uses a parallel group design. During the study, participants will have blood samples taken at baseline, Day 29, and at 3, 6, 9, and 12 months to measure neutralizing antibodies and immunoglobulin G concentrations against RSV and HMPV. Safety will be monitored through reporting of adverse events shortly after vaccination, for several days post-vaccination, and up to six months or throughout the 12-month study period. Biological tests and medical assessments will also be performed to ensure participant safety and collect detailed data on immune response.

Age: 60Years +All GendersPhase 1Phase 2
50 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations